Diane West

The Politics and Policy page provides a concise and timely round-up of key government-related oncology and biotechnology news. Content is focused upon the public sector activities that are most likely to impact the evolving oncology and biotech industries.

This issue features reports from: American Association for Cancer Research meeting April 14-18, 2007 Los Angeles, CA BIO International Convention May 6-9, 2007 Boston, MA

The articles featured in this issue are: 1) Supplemental Drug Application Submitted for Postoperative Nausea and Vomiting by John D. Zoidis, MD 2) Medicare Proposes Limits on Coverage for Erythropoiesis-Stimulating Drugs by John D. Zoidis, MD 3) Femara Reduces Risk of Early Breast Cancer Relapse in Postmenopausal Women, and more

At the 101st American Association for Cancer Research (AACR) Annual Meeting in Washington, DC, in April, Pfizer presented a broad overview of its current oncology pipeline.

Key findings from the 2008 ASCO Breast Cancer Conference focus on the latest multidisciplinary research as well as in-depth discussions on how and when to translate new findings into patient care. Highlighted presentations address the need for greater selectivity in choosing a therapy regimen for a specific patient with breast cancer. In particular, what efforts are underway to develop targeted treatments for triple-negative breast tumors?

Key findings from the 2008 ASCO Breast Cancer conference; updates on goserelin, capecitabine, docetaxel & lapatinib.

Breast cancer in general is not openly discussed in Malaysia, but this may be changing.